Released Oct 30, 2024, after the close
10-Q filed Nov 6, 2024, 37 days after period end · 0000950170-24-122473
Q3 2024 · 10-Q
Revenue$22.09M$22.09M −12.9% vs Q3 2023−1.8% vs Q2 2024
Net Income-$26.94M-$26.94M N/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.07-$0.07 N/M vs Q3 2023N/M vs Q2 2024
Gross Profit$12,126,000+8.7%
Operating Income-$26,699,000N/M
Operating Cash Flowderived-$27,869,000N/M
Free Cash Flowderived-$30,124,000N/M
Margins · derived
Gross margin54.9%+10.9 pt vs Q3 2023
Operating margin-120.9%−37.4 pt vs Q3 2023
Net margin-122.0%−39.2 pt vs Q3 2023
What the release said
The release
Same quarter
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $22.09M | $25.37M | $25.65M | $28.50M |
| Net Income | -$26.94M | -$21.00M | -$29.43M | -$13.84M |
| EPS Diluted | -$0.07 | -$0.27 | -$0.37 | -$0.18 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR